Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors

Autologous hematopoietic cell transplantation is covered for high‑risk neuroblastoma when the member meets the transplanting institution’s protocol selection criteria or, if no protocol exists, for patients without comorbid disease that would preclude a durable remission who meet specified stage and n‑myc amplification criteria (e.g., Stage IV, Stage II–III with >10 copies or amplified n‑myc, and recurrent/refractory disease unlikely to respond to conventional therapy). Adoptive cellular immunotherapy from haploidentical or matched donors after HSCT and allogeneic HCT for neuroblastoma, ependymoma, Ewing sarcoma family tumors, and PNETs (including medulloblastoma and pineoblastoma) are considered experimental/investigational and excluded.

"Allogeneic hematopoietic cell transplantation for the treatment of ependymoma (experimental/investigational)."

Sign up to see full coverage criteria, indications, and limitations.